A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO
Portfolio Pulse from The Bamboo Works
Abbisko Therapeutics, a cancer treatment developer, recently went public in Hong Kong, raising $226 million. Despite strong backing from investors like Carlyle Group and Temasek, its stock has declined since the IPO. The company is focusing on developing oncology drugs, including ABSK091, licensed from AstraZeneca, and ABSK081, licensed from X4 Pharmaceuticals.
October 22, 2021 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Abbisko's executive team includes members with experience in developing successful drugs like AbbVie's Venetoclax, highlighting the team's strong background.
The mention of AbbVie's Venetoclax in the context of Abbisko's leadership experience highlights the team's capability but does not directly impact AbbVie's stock.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 30
NEUTRAL IMPACT
Abbisko's SVP of Biology, Dr. Chen Zhui, has a background with Abbott Laboratories, contributing to his expertise in drug development.
Dr. Chen Zhui's experience at Abbott Laboratories is part of his credentials but does not directly affect Abbott Laboratories' stock.
CONFIDENCE 60
IMPORTANCE 30
RELEVANCE 20
NEUTRAL IMPACT
Abbisko's SVP of Biology, Dr. Chen Zhui, has experience from Johnson & Johnson, adding to the company's strong leadership.
Dr. Chen Zhui's past role at Johnson & Johnson adds to his expertise but does not directly impact Johnson & Johnson's stock.
CONFIDENCE 60
IMPORTANCE 30
RELEVANCE 20
NEUTRAL IMPACT
Abbisko's CEO, Dr. Xu Yaochang, has a background with Eli Lilly, contributing to his expertise in drug development.
Dr. Xu Yaochang's experience at Eli Lilly is part of his credentials but does not directly affect Eli Lilly's stock.
CONFIDENCE 60
IMPORTANCE 30
RELEVANCE 20
NEUTRAL IMPACT
Abbisko's SVP of Chemistry, Yu Hongping, has experience from Merck, adding to the company's strong leadership.
Yu Hongping's past role at Merck adds to his expertise but does not directly impact Merck's stock.
CONFIDENCE 60
IMPORTANCE 30
RELEVANCE 20
POSITIVE IMPACT
Abbisko licensed ABSK081 from X4 Pharmaceuticals for development in China. This partnership is crucial for Abbisko's growth strategy.
Abbisko's licensing of ABSK081 from X4 Pharmaceuticals is a significant part of its strategy to expand in the Chinese market. This could positively impact X4 Pharmaceuticals as Abbisko progresses with the drug's development.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70